Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

Affiliations

Comment

Luis Paz-Ares. Lancet Oncol. 2012 Mar.

. 2012 Mar;13(3):225-7.

doi: 10.1016/S1470-2045(12)70001-3. Epub 2012 Jan 24.

¹ Instituto de Biomedicina de Sevilla and Hospital Universitario Virgen del Rocío, Seville, Spain. luis.pazares.sspa@juntadeandalucia.es

No abstract available

Comment on

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Ciuleanu T, et al. Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24. Lancet Oncol. 2012. PMID: 22277837 Clinical Trial.